LAVIANA PHARMA CO, LTD ’s Post

💊 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤 𝐁𝐮𝐢𝐥𝐝𝐬 $𝟐𝟐𝟎𝐌 𝐑𝐚𝐰 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭𝐬 𝐏𝐥𝐚𝐧𝐭 𝐢𝐧 𝐃𝐞𝐧𝐦𝐚𝐫𝐤! 🌟 𝐈𝐧 𝐀𝐮𝐠𝐮𝐬𝐭 𝟐𝟎𝟐𝟒, Novo Nordisk Pharmatech A/S, a unit that specializes in #producing drug ingredients, is spending 𝟏.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 Danish kroner ($220 million) to build a plant in Køge, Denmark, that will make #rawmaterials. Even as supplies of Novo Nordisk’s immensely popular GLP-1 drugs Ozempic and Wegovywire start to #stabilize, the Danish drugmaker continues to announce #manufacturing and #capacity upgrades at a rapid clip. The 8,000-square-meter roughly 86,000-square-foot facility will include production, storage, office and laboratory space, Pharmatech said, adding that the outlay marks the biggest investment in its 75-year history. 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐨𝐮𝐫 𝐂𝐨𝐫𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 👉: https://bit.ly/4dPD2Vw #PharmaInvestment #Denmark #RawIngredients #PharmaInnovation #Pharmaceuticals #IndustryGrowth #DenmarkInvestment #Sustainability #prophecymarketinsights

Supporting the development of domestic biopharmaceutical industry | Fosun Weekly 1) Guo Guangchang：I hope to see more and more diseases being cured 2) Chen Qiyu: Building a multinational pharmaceutical company originating from China, and leading domestic biopharmaceutical industry to the world 3) Xu Xiaoliang: Standing its foothold in oriental lifestyle aesthetics, Shanghai New Customization Week (SNCW) adheres to its original aspirations and starts again after ten years 4) Fosun International Wins "The Asset ESG Corporate Awards 2024 – Platinum Award" and "Best Initiative in Social Responsibility" from The Asset 5) 2025 INFINITE VISONARIES Award officially launched #ESG #sustainableliving #Fashion #Fosun #Fosunweekly #FosunPharma #FosunFoundation #BOIF #innovation #IBIWS #cooperation #SNCW #OrientalLifestyle #Fashion #ESG #TheAsset #Award #sustainableliving

Top Story Novo Nordisk pours $411M into new quality control hub in Denmark #pharma #biopharma #expansion #qualitycontrol #laboratory #investment #denmark https://buff.ly/41iYyir

As the BIOSECURE Act draft legislation moves through Congress, multinational pharmaceutical companies are re-examining their R&D footprints and manufacturing supply chains. In a Nikkei Asia op-ed, TAG VPs Gopal Nadadur and Samuel Ide explain that India still has a ways to go in offering itself as a true alternative to China, but it could get there with new international investment, government’s initiatives, and support from like-minded partners. Read more here: https://lnkd.in/eGaby7D3

Hi everyone! 💊 Exciting developments are happening in the pharmaceutical sector across Europe and emerging markets today. 🚀 From innovative research to cutting-edge technologies, the industry is booming with new product development. 🌟 I'm thrilled to share insights on how countries like the UK, Germany, and Switzerland are paving the way with their advanced manufacturing processes within the pharmaceutical sector. 🇬🇧🇩🇪🇨🇭 Meanwhile, emerging markets such as Poland, Czech Republic, and Hungary are also making significant strides in developing new and groundbreaking products. 🌍 The dedication to quality and innovation in these regions is truly inspiring, shaping the future of healthcare worldwide. 💡 Let's continue to champion progress and excellence in pharmaceutical manufacturing together! 🌐 #PharmaInnovation #EuropeManufacturing #EmergingMarketsSuccess 🌿

🌍 AGC Pharma Chemicals had the challenge of relocating from #Japan to #Catalonia to establish a development center for the European and North American markets, and Catalonia Trade & Investment, through its offices in Japan and Barcelona, supported the company throughout the process. 👨🔬 👩🔬 AGC Pharma Chemicals specializes in manufacturing small-molecule Active Pharmaceutical Ingredients and intermediates. Leveraging Catalonia's strategic location and world-class talent, the company is well-positioned to supply global markets and drive innovation. 🧪Belonging to the AGC Group, a global business conglomerate with a presence in over 30 countries, AGC Pharma Chemicals is making significant strides in the pharmaceutical industry. 🏭 Discover how Catalonia Trade & Investment can help you set up your company with tailored services. 👇 https://lnkd.in/e_jSyJiR. 🤝Connect with us to explore the opportunities that Catalonia has to offer. #InvestInCatalonia #BusinessExpansion #GlobalInvestment 🌍

Mark Your Calendars! 4th Annual Highly Potent Active Pharmaceutical Ingredients Forum at Novotel Berlin Am Tiergarten Calling all pharmaceutical and biotechnology professionals! I'm excited to share news about the 4th Annual HPAPI Forum happening in Berlin, Germany on December 4th & 5th, 2024 (organized by Amistat Group ). Here's what you can expect: 6+ hours of dedicated networking to build valuable connections. 20+ senior speakers sharing their expertise through practical sessions. 20 high-level sessions covering topics like safety regulations, efficient manufacturing practices, and risk mitigation strategies. I'm particularly excited to hear from is Eric White Senior EHS Manager at AbbVie, who will be discussing best practices for HPAPI governance and EHS technology implementation. Don't miss out on this opportunity to: Gain valuable insights from industry experts. Network with peers and potential collaborators. Stay ahead of the curve in the rapidly evolving HPAPI landscape. Register today! https://lnkd.in/d6nEr2Dx for more information and secure your spot. Contact: +420 216 216 676 Please follow, like, and share Amistat Group for updates on the conference! #HPAPI #Pharma #Biotech #Manufacturing #Safety #Networking #Berlin #Novotel #Conference #HPAPIforum #Berlinconference #Pharmaconference #Biotechconference #Drugdevelopment #Manufacturing #Safety #Regulatory #Industry #Networking #Science #Innovation #Healthcare

I had the pleasure of attending the panel hosted by EuropaBio - the European Association for Bioindustries at #BIOEurope, where we discussed European legislations, particularly General Pharmaceutical Legislation (#GPL) and its impact on life science innovations. Alongside industry leaders such as Claire Skentelbery of EuropaBio - the European Association for Bioindustries, Fabrizio Conicella of Chiesi Group, and Joao Incio, MD PhD of Biovance Capital, we examined how #GPL can foster disruptive innovations. It became evident that balanced legislation is vital for the sector to achieve its ambitious goals. Here are some key insights from the conversation: • Establishing an innovation-friendly ecosystem in Europe is crucial. • Investment locations depend on various factors related to the attractiveness of the innovation ecosystem, including the availability of a skilled workforce, academia, scientists, regulatory systems, and the ability to absorb innovation. • There is global competition for the location of innovation. A more friendly ecosystem increases the chances of attracting investments. • Innovators developing novel therapies need predictable legislation and IP. The takeaway message is to ensure that #GPL enhances the EU's strengths for a competitive global position. Thank you for the inspiring conversation. I look forward to continuing the work on building the innovation ecosystem in Europe! #EUCompetitiveness #AccessToInnovation #Innovation #Healthcare #Pharma #BioIndustry 

The IPEL initiative (Integrated Pharma Eco-Lanes) is setting a new standard for sustainable logistics in pharma. By aligning expertise and resources across the sector, we are demonstrating the power of collective action in meeting critical environmental goals. There is no question about the financial benefits of sustainable logistics in the global pharma supply chain. The GDP-UCI IPEL project makes the business case for change while driving a greener future for pharmaceutical distribution.

Citi Pharma Limited has taken a significant step forward in its growth journey by entering into a joint venture with Hangzhou Newsea Technology Co., Ltd. This strategic partnership is poised to generate substantial value, with an anticipated annual turnover exceeding Rs. 15 billion and a gross profit projection of Rs. 4.5 billion. The joint venture, named ETACI LIMITED, will primarily focus on expanding Citi Pharma's product portfolio by venturing into the production of additional Active Pharmaceutical Ingredients (APIs). This strategic move underscores Citi Pharma's commitment to diversification and innovation, leveraging technology transfer to enhance its capabilities in the pharmaceutical sector. By embracing this collaboration, Citi Pharma aims to foster sustainable growth and contribute to Pakistan's economic development. The partnership reflects the company's dedication to fostering self-reliance and harnessing the potential of the pharmaceutical industry to drive prosperity. With the combined expertise and resources of both entities, the joint venture is well-positioned to make a significant impact in the pharmaceutical landscape, offering innovative solutions and driving value for stakeholders. #Pharma #jointventure #Chinese #technologytransfer